Literature DB >> 2109872

Interferon-gamma associated with conventional therapy for recurrent visceral leishmaniasis in a patient with AIDS.

O Lortholary, D Mechali, D Christiaens, M Gougerot Pocidalo, M Brandely, P Babinet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2109872     DOI： 10.1093/clinids/12.2.370

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN： 0162-0886


× No keyword cloud information.
  8 in total

Review 1.  Tropical medicine.

Authors:  G C Cook
Journal:  Postgrad Med J       Date:  1991-09       Impact factor: 2.401

2.  AIDS and leishmaniasis.

Authors:  R N Davidson
Journal:  Genitourin Med       Date:  1997-08

Review 3.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

Review 4.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

5.  Treatment of atypical leishmaniasis with interferon gamma resulting in progression of Kaposi's sarcoma in an AIDS patient.

Authors:  H Albrecht; H J Stellbrink; G Gross; B Berg; U Helmchen; H Mensing
Journal:  Clin Investig       Date:  1994-12

Review 6.  Leishmaniases of the New World: current concepts and implications for future research.

Authors:  G Grimaldi; R B Tesh
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

7.  Short term treatment of visceral leishmaniasis of the Old World with low dose interferon gamma and pentavalent antimony.

Authors:  J van Lunzen; P Kern; J Schmitz; J Brzoska; S Flessenkämper; M Dietrich
Journal:  Infection       Date:  1993 Nov-Dec       Impact factor: 3.553

Review 8.  Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.

Authors:  Wim Adriaensen; Thomas P C Dorlo; Guido Vanham; Luc Kestens; Paul M Kaye; Johan van Griensven
Journal:  Front Immunol       Date:  2018-01-12       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.